SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL GLP-1/FGF21 DUAL AGONIST HEC88473 IN TYPE 2 DIABETES PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1b/2a MULTIPLE-ASCENDING-DOSE STUDY

被引：0
|
作者：
Xiang, Lin [1 ]
Ding, Hua Yan [1 ]
Yan, Jiangyu [2 ]
Luo, Lin [2 ]
Zhang, Hong [1 ]
Xie, Can [2 ]
Peng, Yu Yu [2 ]
Chen, Hong [1 ]
Li, Qian Qian [1 ]
Li, Xiao Ping [2 ]
Zhuang, Yu Lei [2 ]
Guo, Linfeng [2 ]
机构：
[1] First Hosp Jilin Univ, Changchun, Peoples R China
[2] Sunshine Lake Pharma Co Ltd, Donguang, Peoples R China
来源：
HEPATOLOGY | 2024年 / 79卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
5038-C
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [1] Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
    Loomba, Rohit
    Lawitz, Eric J.
    Frias, Juan Pablo
    Ortiz-Lasanta, Grisell
    Johansson, Lars
    Franey, Bridgette Boggess
    Morrow, Linda
    Rosenstock, Moti
    Hartsfield, Cynthia L.
    Chen, Chao-Yin
    Tseng, Leo
    Charlton, R. Will
    Mansbach, Hank
    Margalit, Maya
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (02): : 120 - 132
  • [2] First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
    Zhang, Hong
    Li, Qianqian
    Chen, Hong
    Guo, Lingfeng
    Li, Jing
    Xie, Can
    Yan, Jiangyu
    Ding, Yanhua
    BIODRUGS, 2025, : 477 - 486
  • [3] Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blind, dose-escalation study
    Wang, Maggie
    Kipnes, Mark
    Matheson, Stephanie
    Wen, Stella
    Lawrence, Betty
    Thibaudeau, Karen
    Castaigne, Jean-Paul
    Ulich, Thomas
    DIABETES, 2007, 56 : A133 - A133
  • [4] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    Urva, Shweta
    Coskun, Tamer
    Loh, Mei Teng
    Du, Yu
    Thomas, Melissa K.
    Gurbuz, Sirel
    Haupt, Axel
    Benson, Charles T.
    Hernandez-Illas, Martha
    D'Alessio, David A.
    Milicevic, Zvonko
    LANCET, 2022, 400 (10366): : 1869 - 1881
  • [5] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
    Ambery, Philip
    Parker, Victoria E.
    Stumvoll, Michael
    Posch, Maximilian G.
    Heise, Tim
    Plum-Moerschel, Leona
    Tsai, Lan-Feng
    Robertson, Darren
    Jain, Meena
    Petrone, Marcella
    Rondinone, Cristina
    Hirshberg, Boaz
    Jermutus, Lutz
    LANCET, 2018, 391 (10140): : 2607 - 2618
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects -A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study
    Wu, Jingying
    Hu, Wei
    Du, Yijun
    Zhang, Qian
    Zhou, Renpeng
    Zhang, Qin
    Qin, Huiling
    Ye, Zi
    Xu, Yimei
    Feng, Sheng
    Shu, Chang
    Shen, Yu
    Fan, Yang
    DIABETES, 2023, 72
  • [7] Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
    Zhu, Dalong
    Wang, Weimin
    Tong, Guoyu
    Ma, Guoqing
    Ma, Jianhua
    Han, Jie
    Zhang, Xin
    Liu, Yang
    Gan, Shenglian
    Qin, Hong
    Zheng, Qing
    Ning, Jing
    Zhu, Zhiyi
    Guo, Mengying
    Bu, Yue
    Li, Yao
    Jones, Catherine L.
    Fenaux, Martijn
    Junaidi, Mohammed K.
    Xu, Susan
    Pan, Hai
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [8] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects-A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study
    He, Kun
    Wei, Fang
    Chen, Hong
    Zhang, Yanyan
    Sheng, Zhen
    Wen, Qing
    DIABETES, 2023, 72
  • [9] Selective orexin 2 receptor agonist TAK-925 to treat narcolepsy: results of a randomized, double-blind, placebo-controlled, multiple-ascending-dose, phase 1 study in patients with narcolepsy type 1
    Tanaka, S. -I.
    Evans, R.
    Alexander, R.
    Imazaki, M.
    Touno, S.
    Shimizu, K.
    Wu, J.
    Faessel, H.
    Ratti, E.
    Hartman, D.
    JOURNAL OF SLEEP RESEARCH, 2020, 29 : 72 - 72
  • [10] Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects-A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study
    Yuan, Jiandong
    Huang, Yangqing
    Ding, Haifeng
    Jiang, Xiaohui
    DIABETES, 2024, 73
12345